Bone Alterations Associated with HIV
- 398 Downloads
HIV infection and initiation of antiretroviral therapy (ART) have been consistently associated with decreased bone mineral density (BMD), with growing evidence linking HIV to an increased risk of fracture. This is especially concerning with the expanding number of older persons living with HIV. Interestingly, recent data suggest that HIV-infected children and youth fail to achieve peak BMD, possibly increasing their lifetime risk of fracture. Elucidating the causes of the bone changes in HIV-positive persons is challenging because of the multifactorial nature of bone disease in HIV, including contribution of the virus, immunosuppression, ART toxicity, and traditional osteoporosis risk factors, such as age, lower weight, tobacco, and alcohol use. Thus, practitioners must recognize the risk of low BMD and fractures and appropriately screen patients for osteoporosis if risk factors exist. If fractures do occur or elevated fracture risk is detected through screening, treatment with bisphosphonate medications appears safe and effective in the HIV + population.
KeywordsHIV Bone Osteoporosis Fractures Vitamin D Osteoblasts Children Hepatitis C Treatment Screening Bisphosphonates
Compliance with Ethics Guidelines
Conflict of Interest
Amy H. Warriner has received research funding from NIH, AHRQ, Astra Zeneca, Bristol-Myers Squibb/Amylin; holds a role on the advisory board for Janssen; and has received payment from ISCD and AACE for lectures. Michael Mugavero reports grants from Bristol Meyers Squibb, grants from Definicare, grants from Pfizer for outside the submitted work; and has received consulting fees from Bristol Meyers Squibb, Merck, and Gilead. E. Turner Overton reports other from Gilead Sciences for outside the submitted work.
Human and Animal Rights and Informed Consent
This article does not contain any studies with human or animal subjects performed by any of the authors.
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
- 11.Short CE, Shaw SG, Fisher MJ, et al. Prevalence of and risk factors for osteoporosis and fracture among a male HIV-infected population in the UK. Int J STD AIDS. 2014;25:113–21.Google Scholar
- 14.Aydin OA, Karaosmanoglu HK, Karahasanoglu R, et al. Prevalence and risk factors of osteopenia/osteoporosis in Turkish HIV/AIDS patients. Braz J Infect Dis. 2013;17:707–11.Google Scholar
- 15.Hamill MM, Ward KA, Pettifor JM, et al. Bone mass, body composition and vitamin D status of ARV-naive, urban, black South African women with HIV infection, stratified by CD count. Osteoporos Int. 2013; 24:2855–61.Google Scholar
- 17.McComsey GA, Kitch D, Daar ES, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis. 2011;203:1791–801.PubMedCentralPubMedCrossRefGoogle Scholar
- 26.Cutrell J, Maalouf NM, Zhang S, et al. Mechanism of bone disease in HIV and HCV: impact of tenofovir exposure and severity of liver disease. In: Conference on Retroviruses and Opportunistic Infections. Boston; 2014.Google Scholar
- 29.•Maalouf NM, Zhang S, Drechsler H, et al. Hepatitis C co-infection and severity of liver disease as risk factors for osteoporotic fractures among HIV-infected patients. J Bone Miner Res. 2013;28:2577–83. In this large study of over 56,000 veterans included in a case registry over 25 years, fractures were found to be more prevalent among HIV/HCV co-infected than HIV-infected patients and the degree of liver disease (determined through and indirect assessment of liver fibrosis) partially explained the difference between these groups.PubMedCrossRefGoogle Scholar
- 34.•Hernandez-Vallejo SJ, Beaupere C, Larghero J, et al. HIV protease inhibitors induce senescence and alter osteoblastic potential of human bone marrow mesenchymal stem cells: beneficial effect of pravastatin. Aging Cell. 2013;12:955–65. Osteoblast development was altered when exposed in vitro to protease inhibitors. The senescence and oxidative stress seen with PI exposure was partially reversed with antioxidants and prevented with pravastatin exposure.PubMedCrossRefGoogle Scholar
- 36.Titanji K, Vunnava A, Sheth A, et al. Dysregulation promotes HIV-induced bone loss. In: Conference on Retroviruses and Opportunistic Infections: Atlanta; 2013.Google Scholar
- 37.Overton ET, Mondy K, Bush T, et al. Factors associated with low bone mineral density in a large cohort of HIV-infected US adults: baseline results from the SUN Study. In: Conference on Retroviruses and Opportunistic Infections: Los Angeles; 2007.Google Scholar
- 38.Masyeni S, Utama S, Somia A, et al. Factors influencing bone mineral density in ARV-naive patients at Sanglah Hospital. Bali Acta Med Indones. 2013;45:175–9.Google Scholar
- 40.••Hoy J, Grund B, Roediger M, et al. Interruption or deferral of antiretroviral therapy reduces markers of bone turnover compared with continuous therapy: the SMART body composition substudy. J Bone Miner Res. 2013;28:1264–74. This study provides further information on the changes in bone turnover in the pivotal SMART study, showing differences in bone turnover between the interrupted treatment vs the continuous treatment groups.PubMedCentralPubMedCrossRefGoogle Scholar
- 41.•Assoumou L, Katlama C, Viard JP, et al. Changes in bone mineral density over a 2-year period in HIV-1-infected men under combined antiretroviral therapy with osteopenia. AIDS. 2013;27:2425–30. Compared with other ART regimen, patients treated with tenofovir were found to have significant loss of BMD over a 2-year period.PubMedCrossRefGoogle Scholar
- 44.•Bloch M, Tong W, Hoy J, et al. Switch from tenofovir to raltegravir increases low bone mineral density and decreases markers of bone turnover over 48 weeks. HIV Med. 2014;15:373–80. In this pilot study of 37 patients, switching from tenofovir to raltegravir led to significant improvement in BMD at the hip and spine. Google Scholar
- 45.Havens PL, Kiser JJ, Stephensen CB, et al. Association of higher plasma vitamin D binding protein and lower free calcitriol levels with tenofovir disoproxil fumarate use and plasma and intracellular tenofovir pharmacokinetics: cause of a functional vitamin D deficiency? Antimicrob Agents Chemother. 2013;57:5619–28.PubMedCentralPubMedCrossRefGoogle Scholar
- 47.Overton E, Chan E, Brown T, et al. High-dose vitamin D and calcium attenuates bone loss with ART initiation: results from ACTG A5280. In: Conference on Retroviruses and Opportunistic Infections: Boston; 2014.Google Scholar
- 50.Manavalan JS, Arapdi S, Shah J, et al. Replicative senescence of circulating osteogenic cells and low BMD in perinatally infected men. In: Conference on Retroviruses and Opportunistic Infections: Boston; 2014.Google Scholar
- 51.Brown T, Moser C, Currier J, et al. Bone density changes after antiretroviral initiation with protease inhibitors or raltegravir. In: Conference on Retroviruses and Opportunistic Infections: Boston; 2014.Google Scholar
- 52.•Martin A, Moore C, Mallon PW, et al. Bone mineral density in HIV participants randomized to raltegravir and lopinavir/ritonavir compared with standard second line therapy. AIDS. 2013;27:2403–11. Raltegravir led to significantly less bone loss than nucleoside/nucleotide regimen in this study of 210 patients.PubMedCentralPubMedCrossRefGoogle Scholar
- 53.Tebas P, Kumar P, Hicks C, et al. 48 Week bone marker changes with dolutegravir (DTG; GSK1349572) plus abacavir/lamivudine (ABC/3TC) vs tenofovir/emtricitabine/efavirenz (EFV/TDF/FTC): the SINGLE Trial. In: Interscience Conference on Antimicrobial Agents and Chemotherapy: Denver; 2013.Google Scholar
- 56.•Borderi M, Calza L, Colangeli V, et al. Prevalence of sub-clinical vertebral fractures in HIV-infected patients. New Microbiol. 2014;37:25–32. In this study of 202 patients, lateral vertebral x-rays were completed revealing vertebral fractures in 23 % of patients, raising the concern of occult vertebral fractures in the HIV + population.PubMedGoogle Scholar
- 57.••Yin MT, Lund E, Shah J, et al. Lower peak bone mass and abnormal trabecular and cortical microarchitecture in young men infected with HIV early in life. AIDS. 2014;28:345–53. In this cross-sectional study of African-American and Hispanic men who were infected with HIV during childhood or adolescence, peak bone mass was lower than in HIV uninfected men and bone microachitecture was altered.PubMedCentralPubMedCrossRefGoogle Scholar
- 58.•DiMeglio LA, Wang J, Siberry GK, et al. Bone mineral density in children and adolescents with perinatal HIV infection. AIDS. 2013;27:211–20. In this cross-sectional study of children in the U.S. and Puerto Rico, lower BMD was seen in the HIV + than expected, which was partially explained by delayed growth.PubMedCrossRefGoogle Scholar
- 60.Manavalan JS, Arapdi S, Shah J, et al. Replicative senescence of circulating osteogenic cells and low BMD in perinatally infected men. In: Conference on Retroviruses and Opportunistic Infections: Boston; 2014.Google Scholar
- 61.Diseases and Conditions that May Cause Bone Loss. Available at: http://nof.org/articles/5.
- 67.Battalora L, Buchacz K, Armon C, et al. New fracture risk and FRAX 10-year probability of fracture in HIV-infected adults. In: Conference on Retroviruses and Opportunistic Infections: Boston; 2014.Google Scholar
- 68.•Assa A, Vong L, Pinnell LJ, et al. Vitamin D deficiency promotes epithelial barrier dysfunction and intestinal inflammation. J Infec Dis. 2014. This study of rodents shows evidence supporting a role of vitamin D in defending against intestinal pathogens. Google Scholar
- 70.•Wohl DA, Orkin C, Doroana M, et al. Change in vitamin D levels and risk of severe vitamin D deficiency over 48 weeks among HIV-1-infected, treatment-naive adults receiving rilpivirine or efavirenz in a Phase III trial (ECHO). Antivir Ther. 2014;19:191–200. In this phase III trial of rilpivirine vs efavirenz in ART-naïve patients, rilpivirine had neutral effects on vitamin D, compared with a significant reduction in 25OH vitamin D in efavirenz treated patients.PubMedCrossRefGoogle Scholar
- 82.Negredo E, Bonjoch A, Pérez-Álvarez N, et al. A randomized open label study for comparing two doses of zoledronic acid in HIV infected patients. In: Conference on Retroviruses and Opportunistic Infections: Boston; 2014.Google Scholar
- 86.Alendronate Medication Insert. Available at: http://www.merck.com/product/usa/pi_circulars/f/fosamax/fosamax_pi.pdf. 2012. Accessed 14 Feb 2014.